Norwegian version of this page

Psychiatric Molecular Genetics Group

The goal of the Psychiatric Molecular Genetics Group at the Department of Medical Genetics is to develop a strong research environment in molecular genetics of psychiatric disorders. The group is part of CoE NORMENT, which is a major collaborative effort studying clinical characteristics, neurocognitive functioning and brain biology of psychotic disorders.

Photo: NORMENT

Aims

The group’s current research aims are to perform molecular genetic analysis to increase the knowledge and expertise in psychiatric genetics and genomics and to identify the molecular networks underlying psychiatric disease as well as to continually develop an organization to support psychiatric genetic and stem cell studies with design and planning.

We have established the required competence and facilities for human induced pluripotent stem cell (hiPSC) technology unit in our Centre allowing investigation of neuronal cells from participants. Validated iPSCs will be differentiated to neural progenitor cells (neural conversion) and regionalized neuronal subtypes, as well as astrocytes/ glial populations under in house methods. We also want to develop psychopharmacological screening platform for psychiatric disorders using iPSC-derived neurons.

Our efforts in identifying the polygenic basis of the human brain and neurodevelopmental disorders resulted in several translational studies published and we aim to further studies elucidating deep molecular phenotyping.

Projects

  • Human induced pluripotent stem cell (hiPSC) technologies in psychiatric molecular genetics
  • Identifying the polygenic basis of the human brain and neurodevelopmental disorders
  • Prediction of longitudinal outcome and brain phenotype by polygenic scores
  • Identification of genetic loci associated with neurocognitive and MR phenotypes and implications for disease mechanisms in severe mental disorders
  • Cooperation and biobanking with the national cohorts and further collaboration with other large-scale studies for validation and QC steps

Cooperation

It is of vital importance to base genetic discovery on large samples, which is difficult to obtain without international collaboration. The Psychiatric Molecular Genetics Group participates in several large European studies of schizophrenia genetics, the SGENE-plus group (coordinated by deCODE, and including research groups as well as samples from England, Germany, Finland, Denmark, Iceland, Scotland) and Scandinavian Collaboration on Psychiatric Etiology (SCOPE),

 

Further, the Psychiatric Molecular Genetics Group is a member of the Psychiatric Genetics Consortium (PGC) which includes all GWAS studies in psychiatric genetics, as well as European IPSC Consortium for Neuropsychiatric Disorders (EURICND)

Published Nov. 13, 2018 9:17 AM - Last modified Jan. 8, 2020 12:29 PM